To the Editor:

A lack of correlation between systemic and local IgE production at mucosal sites has been reported for allergic asthma \[[@C1]--[@C5]\], allergic rhinitis \[[@C6], [@C7]\] and chronic rhinosinusitis with nasal polyps \[[@C8]--[@C10]\]. In allergic asthmatics, local IgE production is higher than in nonallergic asthmatics \[[@C3]\] and high local IgE levels have been linked to the clinical phenotype. Interestingly, in cases of nasal polyps, local IgE targets mainly superantigens \[[@C8]\].

We recently described elevated levels of the epithelial type 2 cytokine interleukin-33 in the bronchoalveolar lavage fluid (BALF) of patients suffering from cystic fibrosis (CF), which represents a strong upstream signal directly affecting resident innate lymphoid cells, tissue resident eosinophils, mast cells and basophils, as well as Th2 cells \[[@C11]\]. In the lungs of patients with cystic fibrosis, a local Th2- and Th17-biased inflammatory immune milieu with considerable numbers of eosinophils and a combined restrictive and obstructive lung function pattern is observed \[[@C12]\]. *Aspergillus fumigatus*- and *Pseudomonas aeruginosa*-specific T-cell lines from CF patients displayed a Th2/Th17 polarisation pattern. Moreover, the rate of allergic sensitisation to *A. fumigatus* is frequent in CF patients \[[@C12]\]. The relevance of this sensitisation is often unclear and in most of the cases, not linked to the picture of allergic bronchopulmonary aspergillosis (ABPA) \[[@C13]\].

Limited data are available regarding to local immunoglobulin production to *A. fumigatus,* and its correlation with CF disease progression or lung function. The current study aimed to investigate whether evidence for local immunoglobulin production to *A. fumigatus* in the lung of CF patients can be found and to what extent this BALF-derived IgE correlates with serum IgE. Moreover, we were interested in the link between *A. fumigatus* in the lung and local immunoglobulin response. The study was approved by the ethics committee of the Medical University of Vienna, Vienna, Austria (\#081/2007, 355/2009). BALF was obtained from 49 children and adolescents with CF as described recently (median age 6.7 years) \[[@C12]\]. *A. fumigatus-*specific antibodies (AF-IgE, -IgA and -IgG) were measured in BALF *via* an "in house" ELISA (Swiss Institute of Allergy and Asthma Research, Davos, Switzerland) \[[@C14], [@C15]\]. Sensitisation was defined by serum IgE levels against *A. fumigatus* (ImmunoCAP m3; ThermoFisher, Uppsala, Sweden).

AF-IgE in serum (\>0.35 kU·L^−1^) was observed in 30.6% of the investigated CF patients. In BALF, 47% of the patients had AF-IgG, 81.6% AF-IgA and 32.7% AF-IgE*.* Local, lung-derived, *A. fumigatus-*specific immunoglobulin levels correlated highly with each other (IgA *versus* IgG: r=0.68, p\<0.0001; IgA *versus* IgE: r=0.66, p\<0.0001; IgG *versus* IgE: r=0.81, p\<0.0001). This suggests that local factors may contribute to immunoglobulin levels in the lung. In contrast, serum AF-IgE and BALF AF-IgE lacked a relevant correlation (r=0.24, not significant). This is in line with studies reporting that allergen stimulation directs IgE production at mucosal sites as the lung or nasal mucosa \[[@C2], [@C4], [@C8]\]. D[urham]{.smallcaps} *et al*. \[[@C1]\] were able to show that class switch recombination and somatic hypermutation to IgE occurs locally and independently from serum IgE levels.

To assess the relevance of *A. fumigatus-*specific immunoglobulin levels in BALF and in the lung, subgrouping according to the presence of *A. fumigatus* in BALF was performed. Local *A. fumigatus* immunoglobulins have been detected in the BALF of 10 out of 49 CF patients. Specific IgG and IgA levels were significantly elevated in CF patients positive for *A. fumigatus* compared to CF patients with no evidence for fungal infection (p\<0.05) ([figure 1a](#F1){ref-type="fig"}). AF*-*IgE levels were higher in CF patients with a positive *A. fumigatus* culture (p=0.09). IgA is known to play a critical role in immunity of mucosal sites. It is the most abundant immunoglobulin subtype in secretions as well as in the bronchial mucosa, and functions by binding antigen in order to avoid adherence to epithelial cells. Due to the low amount of lavage fluid available in this paediatric population, we were able to obtain sufficient total RNA from the BALF cell pellet in only nine out of 49 patients. All patients displayed IgA class recombination and IgG1 class recombination was detected in two of these nine patients. This provides additional evidence for the local nature of the measured immunoglobulin production.

![a) In the presence of *Aspergillus fumigatus*, local IgA and IgG levels to *A. fumigatus* are significantly elevated; \*: p\<0.05. b--d) Exclusive IgE production in the lung was associated with a significantly higher lung function as compared to patients that had serum and bronchoalveolar lavage fluid (BALF) *A. fumigatus*-specific (AF)-IgE (p\<0.05, Mann--Whitney U-test). FVC: forced vital capacity; FEV~1~: forced expiratory volume in 1 s.](00067-2017.01){#F1}

Lung function in CF is characterised by chronic structural damage leading to a decline in lung function. Impairment of lung function is the result of a combination of obstructive respiratory disease due to inflammation, mucus impactions and restrictive lung disease due to bronchiectasis and tissue destruction. Thus, local IgE to *A. fumigatus* may correlate with a reduced lung function. ABPA is a complication occurring in ∼9% of CF patients \[[@C8]\] linked to a hypersensitivity reaction to *A. fumigatus.* Basophil activation by *A. fumigatus* correlates with the clinical phenotype \[[@C16]\], and clinical improvement after anti-IgE and antimycotic treatment indirectly suggests a role of IgE and *A. fumigatus* in this context. However, specific IgE in the blood has not been proven to be a very good marker to predict ABPA and other immunoglobulin subclasses have been implicated in ABPA as well.

To assess a potential impact of lung AF-IgE on lung function, patients were subgrouped based on local and systemic AF-IgE (BALF AF-IgE^−^/serum AF-IgE^−^, BALF AF-IgE^+^/serum AF-IgE^−^, BALF AF-IgE^+^/serum AF-IgE^+^ and BALF AF-IgE^−^/serum AF-IgE^+^). Interestingly, the group of patients that had undetectable serum AF-IgE but a positive local response had a significantly higher forced vital capacity than CF patients with serum AF-IgE*.* Although forced expiratory volume in 1 s was not statistically significantly higher (p=0.067), this may be due to the small sample size ([figure 1c](#F1){ref-type="fig"} and d). *Aspergillus* is known to have potent type 2-inducing properties. This is considered to contribute to the pathogenicity of the fungus. Together with the reduced ability of CF patients to clear pathogens \[[@C17]\], this intrinsic type 2-favouring action has been considered the reason for the high rates of sensitisation to *A. fumigatus* in CF patients. However, immune responses restricted to the local sites with no serum AF-IgE production may be a reflection of isolated local immune responses with a lack of atopic representation and consequently, a more efficient repulsion of *A. fumigatus* and other pathogens, resulting in an improved lung function. This needs to be addressed in larger cohorts.

In conclusion, we provide data on local production of antibodies specific to *A. fumigatus* in response to the presence of fungal growth in the lung of CF patients. Consequently, local IgE is not correlated with serum AF-IgE and most interestingly restricted specific AF-IgE responses in BALF were associated with a better lung function.
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